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ABSTRACT
The RNA editing enzyme ADAR is an attractive therapeutic target for mul-

molecules is comparable between cell lines with either knockdown or

tiple cancers. Through its deaminase activity, ADAR edits adenosine to
inosine in double-stranded RNAs. Loss of ADAR in some cancer cell lines
causes activation of the type I IFN pathway and the PKR translational re-

overexpression of ADAR, and cells with unperturbed ADAR expression.
Treatment with neither molecule causes activation of PKR. Finally, treatment with either molecule has no effect on A-to-I editing of multiple

pressor, leading to inhibition of proliferation and stimulation of cell death.
As such, inhibition of ADAR function is a viable therapeutic strategy for
many cancers. However, there are no FDA-approved inhibitors of ADAR.

ADAR substrates. Together, these data show that 8-azaadenosine and 8chloroadenosine are not suitable small molecules for therapies that require
selective inhibition of ADAR, and neither should be used in preclinical

Two small molecules have been previously shown to inhibit ADAR or reduce its expression: 8-azaadenosine and 8-chloroadenosine. Here we show
that neither molecule is a selective inhibitor of ADAR. Both 8-azaadenosine

studies as ADAR inhibitors.

and 8-chloroadenosine show similar toxicity to ADAR-dependent and independent cancer cell lines. Furthermore, the toxicity of both small

Introduction

Significance: ADAR is a good therapeutic target for multiple cancers;
neither 8-chloroadenosine nor 8-azaadenosine are selective inhibitors of
ADAR.

the importance of ADAR expression in many human cancer cell lines, several
groups have proposed the use of ADAR inhibitors as a therapy for lung, breast,

ADAR (encoded by ADAR, also known as ADAR1 or DSRAD) carries out

and thyroid cancers (11–14).

adenosine-to-inosine (A-to-I) editing within double-stranded RNA (dsRNA;
refs. 1–5). By editing dsRNA, it has been proposed that ADAR prevents sensing
of self dsRNAs by dsRNA-binding proteins involved in activation of the type I

There are currently no FDA-approved ADAR inhibitors. However, two small

IFN response and/or control of translation (6–10). Depletion of ADAR in numerous cancer cell lines causes reduced proliferation and increased apoptosis
(11–14). Consistent with its proposed role in preventing dsRNA sensing, loss of
ADAR in many human cancer cell lines leads to activation of the type I IFN
pathway through activation of MAVS and translation repression by activation
of PKR (11–13). The growth phenotype of ADAR depletion can be rescued by
disruption of type I IFN signaling or knockdown of PKR (11–13). Because of
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molecules have previously been reported to either inhibit ADAR or reduce
its expression (14–16). Both of these small molecules are adenosine analogues
(Fig. 1A). 8-azaadenosine has been used as an ADAR inhibitor in multiple
studies involving leukemic stem cells and thyroid cancer cell lines (14, 16). In
thyroid cancer cell lines, 8-azaadenosine has been shown to be very effective
at inhibiting proliferation, even at doses as low as 1–2 μmol/L (14). The use of
8-azaadenosine as an inhibitor of ADAR was initially inspired by a study that
incorporated 8-azaadenosine and other adenosine analogues into an ADAR
substrate to identify modified substrates that would serve to resolve the structure of ADAR (17). In that study, it was observed that an ADAR substrate
containing 8-azaadenosine resulted in improved A-to-I editing (17). As such,
it is conceivable that free 8-azaadenosine could serve as a competitive inhibitor
of ADAR.
Another adenosine analogue, 8-chloroadenosine, has been shown not to in-

doi: 10.1158/2767-9764.CRC-21-0027

hibit the deaminase activity of ADAR itself, but to reduce ADAR expression
(15). Treatment of several breast cancer cell lines with 8-chloroadenosine led to
reduced ADAR expression and induction of cell death. The cell death pheno-

This open access article is distributed under the Creative Commons Attribution
License 4.0 International (CC BY).

type could be rescued by overexpression of wild-type ADAR, but not a dsRNA
binding–deficient mutant of ADAR, suggesting that 8-chloroadenosine could

© 2021 The Authors; Published by the American Association for Cancer Research

have some selectivity toward ADAR.
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FIGURE 1 8-chloroadenosine and 8-azaadenosine inhibit proliferation of ADAR-dependent and ADAR-independent breast cancer cell lines.
A, Structure of adenosine, 8-azaadenosine, and 8-chloroadenosine. B, A graph summarizing the ADAR dependency status of relevant breast cancer
cell lines as previously published. DEMETER2 corresponds to ADAR dependency as determined by RNAi screening (21–23). CERES corresponds to
ADAR-dependency as determined by CRISPR-Cas9 screening (24, 25). A DEMETER2 or CERES score of less than −0.5 is considered “dependent” or
“essential” (21, 24). The ‡ symbol indicates ADAR-dependency status as determined previously (13). C, Dose–response curve for 8-azaadenosine
treatment of several breast cancer cell lines. D, Dose–response curve for 8-chloroadenosine treatment of several breast cancer cell lines. In C and D, cell
viability was measured by CellTiter-Glo 2.0. E, Quantiﬁcation of foci formation. F, Following treatment of several breast cancer cell lines with
8-chloroadenosine (8-chloro) or 8-azaadenosine (8-aza). For all panels, error bars are mean ± SD. In C and D, the large points are the mean of three
independent experiments, and the smaller points are the mean of three technical replicates performed for each experiment. For E, the smaller points
represent the relative foci area from each of three independent experiments and the column represents the mean foci area of the three experiments.

Here we set out to further evaluate the therapeutic potential of 8chloroadenosine and 8-azaadenosine as ADAR inhibitors. Using several
approaches, we show that neither 8-chloroadenosine nor 8-azaadenosine are
selective inhibitors of ADAR: both molecules inhibited growth of ADARdepleted cells, treatment with neither molecule caused activation of PKR, and
treatment with neither molecule reduced A-to-I editing of multiple ADAR substrates. Together, these results do not support the use of 8-azaadenosine or
8-chloroadenosine as ADAR inhibitors, and instead warrant the future search
for novel ADAR inhibitors.
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Cell Culture
Breast cancer cell lines [MCF-7 (RRID:CVCL_0031), SK-BR-3 (RRID:CVCL_
0033), HCC1806 (RRID:CVCL_1258), MDA-MB-468 (RRID:CVCL_0419)]
were obtained from ATCC in 2011. Cell lines have not been authenticated
since purchase from the manufacturer. Mycoplasma testing was performed
PCR in October of 2019 prior to freeze-back. Cell lines were passaged for at
least one month prior to the experiments described here. All cell lines were
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cultured in DMEM (Hyclone) with 10% FBS (Invitrogen), 2 mmol/L glutamine
(Hyclone), 0.1 mmol/L nonessential amino acids (Hyclone), 1 mmol/L sodium

for 19 cycles dropping the annealing temperature 0.2°C each cycle, 98°C for
30 seconds, 68°C for 30 seconds, 72°C for 55 seconds, repeat steps 6–8 for 19

pyruvate (Hyclone), and 2 μg/mL gentamicin (Invitrogen). 8-chloroadenosine
and 8-azaadenosine were purchased from Tocis (catalog numbers: 4436
and 6868).

cycles, 72°C for 5 minutes. For PCR of the MRPS16 and ZDHHC20 editing
sites, the parameters were as follows: 98°C for 30 seconds, 98°C for 30 seconds,
60°C for 30 seconds, 72°C for 30 seconds, repeat steps 2–4 for 39 cycles, 72°C

Viral Production and Transduction
Lentivirus was produced by Turbo DNAfectin 3000 (Lambda Biotech) trans-

of 10 μg/mL protamine sulfate. The cells were selected with puromycin at
2 μg/mL for one day. For analysis of ADAR expression and PKR activation following ADAR knockdown, cells were harvested 96 hours after transduction.

BPNT1_F_Seq primer: 5 -GGAGTCTCGCTCTGTAGCCT-3 , MRPS16_F or
ZDHHC20_F. The chromatograms for all replicates are available in Supplementary Figs. S6–S14. To determine percent editing, raw peak heights were
measured for the edited and unedited base using the program QSVanalyzer
(19). Percent editing was calculated by the following formula for BPNT1:
Percent editing = 100 ×

The sequences for the shRNA-scramble (shSCR) and shADAR were described
and validated previously (13). For ADAR overexpression cell lines, SK-BR-3
cells were transduced with lentivirus produced from pLVX-IRES-Hygro-EV,
pLVX-IRES-Hygro-p110 or pLVX-IRES-Hygro-p150 described previously (18).

Immunoblot

For MRPS16 and ZDHHC20, the primer used for sequencing resulted in a sequence that is the reverse complement of the mRNA sequence, thus editing
was determined by the ratio of T (unedited) to C (edited). Percent editing was
calculated by the following formula for MRPS16 and ZDHHC20:

Cell pellets were lysed and sonicated in RIPA Buffer (50 mmol/L Tris pH 7.4,
150 mmol/L NaCl, 1% Triton X-100, 0.1% SDS and 0.5% sodium deoxycholate)
with 1× HALT Protease Inhibitor (Pierce). Forty micrograms of protein lysate
were resolved on 4%–12% TGX Acrylamide Stain-Free gels (Bio-Rad). Proteins were transferred to polyvinylidene difluoride membrane (Millipore).
The membrane was cut into strips corresponding to the molecular weight of
proteins of interest. The blots were blocked and then probed with the appropriate primary antibodies: ADAR1 (Santa Cruz Biotechnology, sc-73408),
PKR (Cell Signaling Technology, #3072), PKR Thr-446-P (Abcam, ab32036),
GAPDH (Bethyl Laboratories, A300–641A). Primary antibodies were detected
with horseradish peroxidase–conjugated secondary antibodies (Jackson ImmunoResearch) and detection was carried out with Clarity Western ECL
Substrate (Bio-Rad). Chemiluminescence was imaged using a ChemiDoc imaging system (Bio-Rad). Quantification of immunoblots was performed using
Image Lab software (Bio-Rad). The abundance of each protein was normalized
to GAPDH abundance. For PKR and pPKR, two separate gels were resolved,
transferred, and probed for either PKR or pPKR in addition to GAPDH
for both. PKR and pPKR abundance were normalized to GAPDH prior to
normalizing pPKR to PKR. Uncropped immunoblot images are available in
Supplementary Figs. S1–S5.

Analysis of A-to-I Editing
Cells were treated as indicated for 72 hours prior to harvesting of RNA using
the Nucleospin RNA kit (Macherey-Nagel). First-strand cDNA synthesis was
performed using iScript Supermix (Bio-Rad). The cDNA was purified using
the Monarch DNA and PCR Cleanup Kit (New England Biolabs). Regions
around A-to-I editing sites in BPNT1, MRPS16, or ZDHHC20 were amplified
by Q5 Hot Start High-Fidelity 2X Master Mix (New England Biolabs) and the
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Gpeak height
Gpeak height + Apeak height

Percent editing = 100 ×

Cpeak height
Cpeak height + Tpeak height

Quantitative PCR
First-strand cDNA synthesis was performed using iScript Supermix (Bio-Rad)
with RNA isolated for analysis of A-to-I editing (described above). For
qPCR, the primers listed below were used with iTaq SYBR Green (Bio-Rad).
Fold change in RNA expression was determined by the Ct method with
normalization to GAPDH and HPRT1. Primers for qPCR: GAPDH_F 5 GAGTCAACGGATTTGGTCGT-3 , GAPDH_R 5 -GACAAGCTTCCCGT
TCTCAG-3 , HPRT1_F 5 -CTTCCTCCTCCTGAGCAGTC-3 , HPRT1_R 5 TCACTAATCACGACGCCAGG-3 , CMPK2_F 5 -GGCCAACAGTGTGTT
TCGTC-3 , CMPK2_R 5 -CTTTTCTCTGGAGGGGCTGG-3 , CXCL10_F 5 GAACCTCCAGTCTCAGCACC-3 , CXCL10_F 5 -GATGCAGGTACAGCG
TACAG-3 .

Measurement of Cell Viability
Cells were treated as indicated for 96 hours prior to assessment of cell viability
using CellTiter-Glo 2.0 (Promega) per manufacturers’ protocol. Luminescence
was measured for 10 seconds using a Promega Glomax Navigator luminometer.
Dose–response analysis was performed using the R package "drc" (20). A fourparameter log-logistic model (LL.4) was fit to the viability data. For this loglogistic model, the Hill Coefficient, lower limit, and EC50 were allowed to vary
but the upper limit was set to 1. Further details for this analysis can be found in
the GitHub repository below.

Foci Formation Assay

primers: BPNT1_F 5 -TGCTGTGGGAGGCAAGTTAAC-3 and BPNT1_R
5 -GAGTCCGAGGCAGACAGATC-3 , or MRPS16_F 5 -GAAATCGCACA
CTGAAATATCC-3 and MRPS16_R 5 -TTGACTCACAACCATTCTTAG

Five thousand cells were plated for each condition in a 10-cm culture dish. Three
days later, the cells were treated as indicated. After 9 (HCC1806 and SK-BR-3)
to 14 (MCF-7 and MDA-MB-468) days, the cells were washed briefly with 1×

GTC-3 , or ZDHHC20_F 5 -TGCTGTACTAGGAAATGACAGAGC-3 and
ZDHHC20_R 5 -AACATTCTGTGATGCCTAATTTTG-3 . For PCR of the
BPNT1 editing site, the parameters were as follows: 98°C for 30 seconds, 98°C

PBS prior to fixation in 100% methanol. After drying, the cells were stained with
Giemmsa (Sigma-Aldrich) prior to washing excess stain away with deionized
water. The plates were scanned using an ImageScanner III (General Electric).

for 30 seconds, 72°C for 30 seconds, 72°C for 55 seconds, repeat steps 2–4

Foci area was calculated using ImageJ.
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fection of 293T cells with pCMV-VSV-G, pCMV-R8.2, and pLKO.1-puro
for short hairpin RNA (shRNA). Virus was harvested 48 hours posttransfection. Cells were transduced with lentivirus for 16 hours in the presence

for 5 minutes. The PCR products were resolved by agarose gel electrophoresis
and purified using the Monarch Gel Extraction kit (New England Biolabs).
Purified PCR products were Sanger sequenced by Genewiz using either the
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Data Availability Statement
Scripts used for all plots are available on GitHub (https://github.com/cottrellka/
ADAR_5–2021). The data generated in this study are available within the article
and its Supplementary Data files. Data from DepMap used in Fig. 1B can be
obtained here: https://depmap.org/portal/download/.

comparable between ADAR-dependent and independent cell lines, Fig. 1C–D.
For 8-chloroadenosine there was an approximately 0.25 μmol/L EC50 difference between the most sensitive cell line (MCF-7, ADAR-independent)
and the least (HCC1806, ADAR-dependent). Similarly, for 8-azaadenosine
there was a < 1 μmol/L EC50 difference between the most sensitive cell line

Cytotoxicity of 8-Chloroadenosine and 8-Azaadenosine
in Breast Cancer Cell Lines

the ADAR-dependent cell line MDA-MB-468 were similarly sensitive to the
effects of 8-azaadenosine on foci formation. The two cell lines most sen-

Knockdown or knockout of ADAR causes reduced proliferation and increased
cell death in numerous, but not all cancer cell lines (11–14). ADAR dependency has been evaluated through large screening experiments (21–25) and
smaller studies involving knockdown or knockout of ADAR in panels of human cancer cell lines (11–14). Recently, ADAR dependency was evaluated for

sitive to the effects of 8-chloroadenosine on foci formation were MCF-7
and MDA-MB-468, ADAR-independent and ADAR-dependent cell lines, respectively. Taken together, these data show that neither 8-chloroadenosine
nor 8-azaadenosine are selectively cytotoxic toward ADAR-dependent cell
lines.

a panel of human breast cancer cell lines (13). To evaluate the on-target effects of 8-chloroadenosine and 8-azaadenosine, we assessed the effects of each
small molecule on cell viability of breast cancer cell lines previously identified

Cytotoxicity of 8-Chloroadenosine and 8-Azaadenosine
in ADAR-Depleted or ADAR-Overexpressed Cells

to be ADAR-dependent or -independent (Fig. 1B). If 8-chloroadenosine and/or
8-azaadenosine are selective inhibitors of ADAR, it would be expected that
the EC50 for cell viability of each drug would be lower for ADAR-dependent

While the data described in Fig. 1 are consistent with 8-azaadenosine and
8-chloroadenosine lacking selectivity for ADAR, we sought to address this
question more thoroughly by assessing the cytotoxicity of the small molecules

cell lines relative to ADAR-independent cell lines. However, analysis of the effects of each adenosine analogue on cell viability found that the EC50 s were

in ADAR-depleted cell lines. ADAR was knocked-down in two ADARindependent cell lines, SK-BR-3 and MCF-7, Fig. 2A and 2B. The EC50 of
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Results

(SK-BR-3, ADAR-independent) and least sensitive (MDA-MB-468, ADARdependent). These data were largely supported by foci formation analysis
(Fig. 1E–F). The ADAR-independent cell lines SK-BR-3 and MCF-7, and

FIGURE 2 8-chloroadenosine and 8-azaadenosine inhibit proliferation of ADAR-depleted breast cancer cell lines. Immunoblot of ADAR knockdown
in SK-BR-3 (A) and MCF-7 (B). The level of ADAR knockdown is shown below each band, mean ± SD. Five (SK-BR-3) or six (MCF-7) days after
transduction of shSCR or shADAR, the cells were treated with 8-chloroadenosine or 8-azaadenosine for dose response curves. C and D, Dose–response
curves for 8-azaadenosine and 8-chloroadenosine in SK-BR-3 cells with (shADAR) or without (shSCR) ADAR knockdown. E and F, Dose–response
curves for 8-azaadenosine and 8-chloroadenosine in MCF-7 cells with (shADAR) or without (shSCR) ADAR knockdown. In C–F, the large points are the
mean of three independent experiments, the smaller points are the mean of three technical replicates performed for each experiment, error bars are
mean ± SD.
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cell viability for 8-azaadenosine and 8-chloroadeonsine was evaluated for
control (shSCR) or ADAR knockdown (shADAR). If 8-azaadenosine and/or

Treatment with 8-Chloroadenosine or 8-Azaadenosine
has no Effect on A-to-I Editing

8-chloroadenosine are selective inhibitors of ADAR, it would be expected that
ADAR-depleted cells would be less sensitive to each adenosine analogues.
However, the EC50 for each drug was generally similar between shSCR and

To directly test the effects of 8-azaadenoinse and 8-chloroadenosine on the

shADAR transduced cells for both cell lines, Fig. 2C–D and 2E–F. Only for 8chloroadenosine was there a clear difference between the EC50 in shSCR versus
shADAR transduced cells, with shADAR cells having a lower EC50 .

position 1894 in the BPNT1 mRNA was shown to be highly edited (∼75%) in
four different breast cancer cell lines (28). Percent editing can be measured by
Sanger sequencing of PCR amplified cDNA. As inosine pairs most readily with

Since ADAR expression is often elevated in cancer (13, 26, 27), we assessed
the cytotoxicity of 8-chloroadenosine and 8-azaadenosine in SK-BR-3 with

cytosine, reverse transcriptase will incorporate a cytosine at each A-to-I editing event. Sanger sequencing of the PCR product made from the cDNA will
show either an A (for unedited transcripts) or a G (for edited transcripts). We

gether these data, and the data in Fig. 1, show that neither 8-chloroadenosine
nor 8-azaadenosone induce cytotoxicity through selective inhibition of
ADAR.

Treatment with 8-Chloroadenosine or 8-Azaadenosine
does not Activate PKR
Loss of ADAR in ADAR-dependent cells has been shown to cause activation of
the dsRNA sensor PKR (11–13). It has been proposed that loss of A-to-I editing
by ADAR causes accumulation of dsRNA leading to activation and autophosphorylation of PKR (9). Activated PKR represses translation and can induce
cell death (11–13). Selective inhibitors of ADAR would be expected to also cause
significant PKR activation. We evaluated PKR activation upon treatment with
8-chloroadenosine or 8-azaadenosine by immunoblot using a phospho-PKR
(phospho-T446) specific antibody. Unlike knockdown of ADAR, which caused
robust activation of PKR in the ADAR-dependent cell lines HCC1806 and
MDA-MB-468 (Fig. 3A–C), neither 8-chloroadenosine nor 8-azaadenosine induced PKR activation in the same cell lines, Fig. 3D–I. Furthermore, treatment
with neither adenosine analogue caused increased expression of PKR (Supplementary Figs. S2 and S4). These data suggest that neither 8-chloroadenosine
nor 8-azaadenosine are inhibitors of ADAR.

Treatment with 8-Chloroadenosine or 8-Azaadenosine
does not Phenocopy the Effects of ADAR Knockdown on
ISG Expression

60

performed this analysis to assess the change in A-to-I editing of BPNT1-A1894
upon ADAR knockdown. Knockdown of ADAR reduced editing by approximately 3-fold (Fig. 4A and B). The same analysis was performed for cells treated
with either 1 or 10 μmol/L 8-azaadenosine or 8-chloroadenosine. There were
no substantial changes to editing of BPNT1-A1894 upon treatment with either adenosine analogue (Fig. 4C–F). To extend these findings, we assessed
editing of two additional A-to-I editing sites previously shown to be highly
edited in breast cancer cell lines – MRPS16-A2231 and ZDHHC20-A2877 (28).
Like the BPNT1-A1894 site, knockdown of ADAR caused reduce editing of
both MRPS16-A2231 and ZDHHC20-A2877 (Fig. 4G and H). However, there
were no substantial changes to editing of either site upon treatment with 1 or
10 μmol/L 8-azaadenosine or 8-chloroadenosine in either MDA-MB-468 or
HCC1806 cell lines (Fig. 4I–L). Together, these data clearly show that neither
8-chloroadenosine nor 8-azaadenosine affects A-to-I editing of three separate
editing sites.

Discussion
Several recent studies have highlighted the importance of ADAR expression
in a wide range of cancer cell lines (11–14). In ADAR-dependent cells, loss of
ADAR causes activation of PKR and the type I IFN pathway leading to reduced
proliferation and apoptosis. Furthermore, depletion of ADAR in cell lines that
do not require ADAR expression to grow in tissue culture conditions has been
shown to improve antitumor immunity in vivo, especially in combination with
anti–PD-1 therapies (29). The importance of ADAR in tumor biology therefore
makes it an ideal therapeutic target for multiple cancers.
While there are currently no FDA-approved ADAR inhibitors available for

Loss of ADAR in ADAR-dependent cells has been shown to cause activation
of the type I IFN pathway through activation of MDA5 due to accumulation
of dsRNA (6, 10). Activation of the type I IFN pathway induces transcription

clinical use, two adenosine analogues have been used in preclinical studies to
perturb ADAR activity or expression – 8-chloroadenosine and 8-azaadenosine
(14–16). We found that both adenosine analogues efficiently reduce the via-

of several IFN-stimulated genes (ISG). Selective inhibitors of ADAR would
be expected to also cause type I IFN pathway activation and induced ISG
expression. We evaluated the expression of two ISGs (CMPK2 and CXCL10)

bility of both ADAR-dependent and ADAR-independent cell lines. Similarly,
both adenosine analogues reduced the viability of ADAR-depleted or ADARoverexpressed cell lines to a similar or greater extent than cell lines with

previously shown to be induced upon ADAR depletion (11). Knockdown of
ADAR induced expression of both ISGs in HCC1806, while no induction was
observed in MDA-MB-468 (Fig. 3J and K). Unlike knockdown of ADAR, treat-

unperturbed ADAR expression. We showed that treatment with neither 8chloroadenosine nor 8-azaadenosine caused activation of PKR, in contrast
with ADAR knockdown which caused robust PKR activation in the same cell

ment with 8-azaadenosine did not cause induction of either ISG in HCC1806
(Fig. 3L and M). Treatment with 8-chloroadenosine induced CMPK2 expression in HCC1806, consistent with ADAR knockdown in that cell line (Fig. 3N).

lines. While treatment with 8-chloroadenosine induced expression of one ISG
(CMPK2), it did not phenocopy the effects of ADAR knockdown. Because the
type I IFN pathway can be activated in multiple ways, it is possible that the effect

However, unlike knockdown of ADAR, treatment with 8-chloroadenosine did
not induce expression of CXCL10 (Fig. 3O). Taken together, these data suggest

observed with 8-chloroadenosine is not due to dsRNA accumulation caused by
inhibition of ADAR, which would be consistent with the lack of PKR activation

that neither 8-chloroadenosine nor 8-azaadenosine phenocopy the effects of
ADAR knockdown on ISG expression.

upon 8-chloroadenosine treatment. Finally, we observed that neither adenosine
analogue inhibited A-to-I editing of multiple ADAR substrates.
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or without overexpression of the p110 or p150 isoforms of ADAR. The EC50
of 8-azaadenosine and 8-chloroadeonsine was similar between empty vector
(EV), p110 and p150 overexpressed SK-BR-3, Supplementary Fig. S15. To-

deaminase activity of ADAR, we used Sanger sequencing to measure A-to-I
editing of a highly edited ADAR substrate – BPNT1 (28). The adenosine at
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FIGURE 3 Treatment with 8-chloroadenosine or 8-azaadenosine does not activate PKR. A, Immunoblot showing activation of PKR (increased
phosphorylation of PKR at T446, pPKR) following knockdown of ADAR in HCC1806 and MDA-MB-468. B and C, Quantiﬁcation of the immunoblot in
A. D, Immunoblot showing no activation of PKR following treatment of HCC1806 or MDA-MB-468 with 8-chloroadenosine (8-chloro). E and F,
quantiﬁcation of the immunoblot in B. G, Immunoblot showing no activation of PKR following treatment of (Continued on the following page.)
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(Continued) HCC1806 or MDA-MB-468 with 8-azaadenosine (8-aza). H and I, Quantiﬁcation of the immunoblot in G. J and K, qPCR showing increased
ISG expression following knockdown of ADAR in HCC1806 but not MDA-MB-468. L–O, qPCR assessment of ISG expression following treatment with
8-azaadenosine or 8-chloroadenosine in HCC1806 and MDA-MB-468. For B, C, E, F, and J–O, the smaller points represent relative ADAR abundance,
relative pPKR/PKR, relative CMPK2 abundance or relative CXCL10 abundance from each of three independent experiments, and the column represents
the mean of the three experiments. Error bars are mean ± SD.*, P < 0.05; t test.

addition, 8-chloroadenosine has been shown to activate the unfolded pro-

sistent with what is known about the biological activity of both adenosine
analogues. It has been shown that both adenosine analogues can be incor-

tein response leading to apoptosis in coronary artery endothelial cells (32).
Finally, in vivo studies of 8-azaadenosine toxicity revealed significant hepatic

porated into nascent RNA and DNA (30–32), and inhibit DNA synthesis (31,
33). Furthermore, both 8-azaadenosine and 8-chloroadenosine can be rapidly
incorporated into the cellular ATP pool, replacing ATP with 8-azaATP or 8-

toxicity (34). Taken together, these previous findings, along with those presented here, show that 8-chloroadenosine or 8-azaadenosine likely cause cell
death through numerous indirect effects and not through selective inhibition

chloroATP (32–35). 8-chloroadenosine has also been shown to cause inhibition
of mTOR and activation of AMPK in renal cell carcinoma cell lines (36). In

of ADAR. Neither 8-azaadenosine nor 8-chloroadenosine should be used as
ADAR inhibitors.

FIGURE 4 Treatment with 8-chloroadenosine or 8-azaadenosine does not affect A-to-I editing. A, Sanger sequencing chromatogram of
BPNT1 with or without ADAR knockdown. The arrow indicates a base edited by ADAR. The editing site is at position 1894 within the BPNT1
transcript (NM_006085.6). B, Quantiﬁcation of percent editing as measured by Sanger sequencing in A. Percent editing was calculated as the
edited base (G) peak height divided by the total peak height of the unedited (A) and edited (G) base. C, Sanger sequencing chromatogram of
BPNT1 with or without 8-azaadenosine (8-aza) treatment. D, Quantiﬁcation of percent editing from C. E, Sanger sequencing chromatogram of
BPNT1 with or without 8-azaadenosine (8-aza) treatment. F, Quantiﬁcation of editing efficiency from E. (Continued on the following page.)
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The off-target effects of either 8-chloroadenosine or 8-azaadenosine are con-

Lack of ADAR Inhibitors

or 8-chloroadenosine in HCC1806 and MDA-MB-468. For B, D, and F–L, the smaller points represent percent editing from each of three independent
experiments, and the column represents the mean of the three experiments. Error bars are mean ± SD.
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